Clinical trial NCT00537407: A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Official title: An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who Are Non Responders to Standard Peginterferon Alpha and Ribavirin Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Hepatitis C
Keywords: Hepatitis
Hepatitis C
Lead sponsor: Debiopharm International SA
Sponsor class: INDUSTRY
First posted: 2007-10-01
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Debio 025 (alisporivir) is an oral cyclophilin inhibitor with a new mechanism of action demonstrating potent anti-hepatitis C virus (HCV) activity in pre-clinical models and patients.

The current standard of care (SOC) in HCV patients consists of a combination of peg-IFN alpha and ribavirin. Treatment duration and ribavirin dose depend on the genotype treated. Only 40-50% of patients with genotype 1 achieve a sustained viral response (SVR). This study assesses whether Debio 025 administered in combination with peg-IFN alpha 2a and ribavirin can improve the outcome of treatment in this group of patients.

Detailed description: This is a multicentre, open-label, randomized, 5 arm parallel-group, multiple dose study in 50 chronic hepatitis C virus (HCV) genotype 1 non-responders to standard treatment with peg-IFN alpha (2a or 2b) and ribavirin. The entire study lasts a maximum of 96 weeks and consists of a 48- or 72-week treatment period (according to response). A follow-up visit to assess the sustained viral response (SVR) takes place 24 weeks after treatment cessation, i.e., at study Week 72 or 96, or earlier for discontinued study participants.

There were 2 parts in the treatment period. Part 1 lasted from Day 1 to Day 29 (Weeks 1 to 4); Part 2 lasted from Week 5 to Week 48 or 72.

During Part 1 of treatment (Weeks 1 to 4), participants are randomized to 1 of 5 treatment arms and receive 4 weeks of Debio 025 (alisporivir) monotherapy, Debio 025 combined with standard dose peg-IFNα2a, or 1 of 3 triple therapies combining different doses of Debio 025 with peg-IFNα2a and ribavirin at standard doses.

During Part 2 of treatment (Weeks 5 to 48 or 72), participants receive standard doses of peg-IFNα2a/ribavirin dual therapy for 44 or 68 weeks, depending on their response to treatment. At Week 12, participants who do not achieve ≥ 2 log10 decrease in HCV RNA are withdrawn and considered treatment failures. Participants who have undetectable HCV RNA levels and/or ≥ 2 log10 decrease in HCV RNA continue treatment until Week 24. At Week 24, participants who still have detectable HCV RNA levels are withdrawn and considered treatment failures. Participants with undetectable HCV RNA levels at Weeks 12 and 24 continue treatment until Week 48. At Week 24, "slow responders" (defined as participants with a detectable, but \> 2 log10 decrease in HCV RNA levels at Week 12 and undetectable levels at Week 24) are eligible to continue treatment until Week 72.

Eligibility criteria: Inclusion Criteria:

* Male and female patients between 18 and 60 years of age.
* Hepatitis B negative and human immunodeficiency virus (HIV) negative.
* Diagnosed with hepatitis C genotype I and not responsive to treatments such as peginterferon alpha-2a or 2b and ribavirin for at least 12 weeks.
* Adequate liver function (Child-Pugh-Turcotte score A) and other laboratory parameters within acceptable range.
* Females may participate only if they cannot become pregnant, i.e., are surgically sterile, post-menopausal, or using 2 reliable contraceptive methods.
* Male patients must be surgically sterile or utilizing a barrier contraceptive method.
* For female patients of child bearing potential, negative pregnancy test within 1 week of first investigational product administration.

Exclusion Criteria:

* Treatment with any investigational drug within 6 months prior to the start of the study.
* Ongoing or recent use of antiviral medication within 1 month before the start of the study.
* A known bad reaction or intolerance to Debio 025, peginterferon alpha-2a, and/or ribavirin.
* Presence or history of any severe related disease.

Primary outcomes:
measure: Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)
timeFrame: Baseline to Day 29
Secondary outcomes:
measure: Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)
timeFrame: Baseline to Day 29
measure: log10 Hepatitis C Virus RNA at Day 29
timeFrame: Day 29
measure: Percentage of Participants With a Rapid Viral Response at Day 29
timeFrame: Day 29
measure: Percentage of Participants With an Early Viral Response at Week 12
timeFrame: Baseline to Week 12
measure: Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)
timeFrame: End of treatment (Week 48 or 72)
measure: Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)
timeFrame: 24 weeks after the end of treatment (Week 72 or 96)
Other outcomes:
Locations:
city: la Jolla
country: United States
facility: Scripps Clinic Liver Disease Research Center
state: California
city: Gainesville
country: United States
facility: University of Florida
state: Florida
city: Miami
country: United States
facility: University of Miami Center for Liver Diseases
state: Florida
city: Baltimore
country: United States
facility: The Johns Hopkins University School of Medicine
state: Maryland
city: Dallas
country: United States
facility: Methodist Transplant Physicians
state: Texas
city: Fairfax
country: United States
facility: Metropolitan Research
state: Virginia
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
Study officials:
affiliation: Debiopharm International S.A.
name: Raf Crabbé, MD
role: STUDY_DIRECTOR
References: